Development of a sensitive novel diagnostic kit for the highly pathogenic avian influenza A (H5N1) virus by Yasuko Tsunetsugu-Yokota et al.
RESEARCH ARTICLE Open Access
Development of a sensitive novel diagnostic kit
for the highly pathogenic avian influenza A
(H5N1) virus
Yasuko Tsunetsugu-Yokota1,2*, Kengo Nishimura3, Shuhei Misawa3, Mie Kobayashi-Ishihara1, Hitoshi Takahashi4,
Ikuyo Takayama4, Kazuo Ohnishi1, Shigeyuki Itamura4, Hang LK Nguyen5, Mai TQ Le5, Giang T Dang6,
Long T Nguyen6, Masato Tashiro4 and Tsutomu Kageyama4
Abstract
Background: Sporadic emergence of the highly pathogenic avian influenza (HPAI) H5N1 virus infection in humans
is a serious concern because of the potential for a pandemic. Conventional or quantitative RT-PCR is the standard
laboratory test to detect viral influenza infections. However, this technology requires well-equipped laboratories and
highly trained personnel. A rapid, sensitive, and specific alternative screening method is needed.
Methods: By a luminescence-linked enzyme immunoassay, we have developed a H5N1 HPAI virus detection kit
using anti-H5 hemagglutinin monoclonal antibodies in combination with the detection of a universal NP antigen
of the type A influenza virus. The process takes 15 minutes by use of the fully automated luminescence analyzer,
POCube.
Resutls: We tested this H5/A kit using 19 clinical specimens from 13 patients stored in Vietnam who were infected
with clade 1.1 or clade 2.3.4 H5N1 HPAI virus. Approximately 80% of clinical specimens were H5-positive using the
POCube system, whereas only 10% of the H5-positive samples were detected as influenza A-positive by an
immunochromatography-based rapid diagnostic kit.
Conclusions: This novel H5/A kit using POCube is served as a rapid and sensitive screening test for H5N1 HPAI
virus infection in humans.
Keywords: H5 hemagglutinin, Highly pathogenic avian influenza virus, Rapid influenza diagnosis, Monoclonal
antibody, Clinical specimens
Background
Influenza viruses belong to the Orthomyxovirus family,
whose genome is composed of eight segments of
negative-sense RNA encoding 12 proteins. Two major
glycoproteins, hemagglutinin (HA) and neuraminidase
(NA), are located on the viral envelope, and 16 HA sub-
types and 9 NA subtypes of avian influenza A have been
identified on the basis of their antigenicities [1,2]. There
are three types of influenza virus, namely, A, B, and C.
Influenza A (both H1N1 and H3N2 subtypes) and influ-
enza B viruses circulate among the human population
each year and are the causative agents of seasonal flu.
There have been several pandemics of influenza A infec-
tions, which have resulted in the deaths of many humans
and animals [2,3]. The high variability of influenza A
viruses is driven by frequent mutations in genomic RNA
(drift) and by genetic reassortment among avian,
porcine, and human strains [4]. This has hampered the
development of a universal cross-protective flu vaccine.
The 2003 and 2004 outbreaks of the highly pathogenic
avian influenza (HPAI) virus of subtype H5N1 that
occurred in poultry and wild birds were genetically
traced back to the H5N1 HPAI virus that caused the first
outbreak in Hong Kong in 1997, and also those of 2001
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and 2002 [5]. This report stated that although the H5N1
HPAI virus remained endemic to that region, it had the
potential to become pandemic. The H5N1 HPAI virus
has occasionally crossed the species barrier to humans
in Asia, resulting in human fatalities [6,7], the first of
which was recorded in Vietnam in December 2003 [8].
Numerous clinical cases of H5N1 HPAI virus infections
have since been reported in Vietnam, and the disease
has spread to other countries in Southeast Asia and the
Middle East such as Indonesia, Cambodia, Thailand,
Egypt, and Turkey [7,9].
The H5N1 HPAI virus has evolved into many phylo-
genetically distinct clades and subclades, and these
diverse lineages have been largely geographically sepa-
rated since 2005 [9]. During 2007 in northern Vietnam,
the clade 1 virus was displaced by the clade 2.3.4 strain
that has a different antiviral susceptibility profile [10,11].
The diversity of this virus is continuing to expand
[3,12,13]. Although the earlier endemic outbreak of the
avian H5N1 HPAI virus appears to be under control, the
threat of a human influenza pandemic remains.
PCR-based molecular tests are one of the most sensi-
tive ways to detect the influenza virus, and conventional
and real-time RT-PCR methods have been developed to
diagnose H5N1 HPAI virus infections in humans [14-16].
However, only centralized and well-equipped laboratories
with trained personnel can perform these analyses. Viral
antigen detection using antibodies (Abs) offers an easier
and quicker diagnostic test; however, commercially avail-
able rapid detection kits for influenza A and B have poor
clinical sensitivity for the identification of H5N1 HPAI
infection [9]. Using previously prepared monoclonal
antibodies (mAbs) against influenza A virus HA of the H5
subtype [17], we developed a rapid, sensitive, and H5N1
HPAI virus-specific diagnostic test kit for H5 HA in com-
bination with detection of the universal NP antigen of type
A influenza (H5/A kit), which is processed by a compact
and fully automated luminescence analyzer, POCube
(Toyobo Co Ltd., Osaka, Japan). In this study, we evalu-
ated this novel H5/A diagnostic kit using clinical speci-
mens infected with the H5N1 HPAI virus (genetically
confirmed) in Vietnam and demonstrated the sensitive
dual detection of H5 HA and type A nucleoprotein (NP)
antigens for the first time. Despite of a limited number of
available H5N1 clinical specimens, our results strongly
suggest that this diagnostic test is a useful tool in the rapid
and reliable identification of H5N1 HPAI virus infections.
Methods
POCube system
The POCube is a fully automated and compact immuno-
logical analyzer developed by Toyobo Co. Ltd, which is
intended to support the Point-of-Care Testing (POCT)
system in clinics. The POCube analyzer is relatively
small (280 × 310 × 275 mm), easy to operate, and rapidly
measures antigen-Ab complexes by the sensitive detec-
tion of luminescence (Figure 1). The POCube system
has been used in clinics to detect C-reactive protein
(CRP), prostate antigen, influenza A and B viruses,
respiratory syncytial virus, in combination with kits
authorized by the Ministry of Health, Labour and Welfare
in Japan. The principle of the POCube system is to use two
mAbs and/or polyclonal Abs that have distinct specifi-
cities, where one is biotinylated and the other is con-
jugated to alkaline phosphatase (ALP). The immune
complexes are trapped by an anti-biotin Ab-coated filter
membrane in a reaction vessel and the activity of ALP is
measured by luminescence output. The whole process
takes 5–15 min (depending on the kit), the result is
expressed as a luminescence count, and a clinical diagno-
sis is indicated as “positive” or “negative”.
The H5/A kit consists of one cartridge containing two
reaction vessels with an anti-biotin Ab-coated filter
membrane and following solutions in each compartment
of the reservoir tank sealed with an aluminum sheet
(Figure 1); a biotinylated anti-H5 HA mAb and a ALP-
conjugated anti-H5 HA mAb solutions to detect H5 HA
antigens, a commercially available biotinylated and ALP-
conjugated mAb set against the type A influenza NP
antigen, washing buffer, and a luminescent substrate
(APS-5, Lumigen, Inc., Southfield, MI). Up to 180 μl of
sample is placed into the first empty reservoir tank
within the cartridge. When the POCube operation is
started, the sample solution is transferred to reservoir
tanks containing each set of Abs and allowed to react at
40°C before the immune complex consisting of antigen,
biotinylated Ab and ALP-conjugated Ab is formed. Each
reaction solution is then transferred to each vessel and
trapped on an anti-biotin Ab-coated filter membrane.
The filter membrane is washed with buffer in the tank,
substrate is added to each vessel, and the chemilumines-
cence is measured. The program is set to indicate a posi-
tive or negative result for H5 HA and type A influenza
virus antigens based on a predetermined cut-off index
set that is calculated by adding four standard deviations
(SDs) to the average of eight measurements for the
negative control. The luminescence counts for eight
negative controls in the lot used to test clinical speci-
mens from Vietnam were 1939–2717 (average, 2242; SD,
292) for H5 HA and 1779–2354 (average, 2027; SD, 221)
for type A influenza. Thus, the cut-off indices were set
at 3410 and 2911, respectively.
The sensitivity of the kit was compared with that of
the ESPLINE® Influenza A&B-N (Fujirebio, Inc., Tokyo,
Japan) kit, which is a commercially available rapid influ-
enza diagnostic test (RIDT). This immunochromatogra-
phy (IC)-based kit is meant to diagnose infection by all
type A influenza viruses, including H5N1. However,
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because this kit uses an NP-specific antibody, it cannot
discriminate H5N1 from other subtypes.
Virus preparation
The A/Vietnam/1194/2004 (NIBRG-14) virus, which has
a modified HA gene and an NA gene derived from the
HPAI A/Vietnam/1194/2004 (H5N1) virus within the
backbone of six other internal genes of A/Puerto Rico/8/
34 (PR8), as well as other modified H5N1 viruses, A/
Indonesia/5/2005 (Indo5/PR-8-RG2), A/turkey/Turkey/
1/2005 (NIBRG-23), and A/Anhui/01/2005 (Anhui01/
PR8-RG5), were provided by the National Institute for
Biological Standards and Controls (Potters Bar, UK). The
following subtypes of influenza A viruses were also used
to evaluate the specificity of the POCube H5/A kit and
were obtained from the Influenza Virus Research Center
Figure 1 Principle of the POCube system. POCube is a fully automated chemiluminescence analyzer. In the H5/A kit, two Abs were incorporated,
namely, one for H5 HA and the other for type A NP antigens of the influenza virus. One of the Abs is biotinylated and the other is conjugated to ALP.
A sample is loaded into a reservoir tank in the cartridge, which is placed in the machine along with two reaction vessels. When the complex of
antigen and two Abs is formed, it is trapped on an anti-biotin Ab-coated membrane in the reaction vessels. The membrane is then washed, a
luminescent substrate for ALP is added, and the emitted luminescence is measured. Using the appropriate program, POCube automatically performs
each of these steps, and the result is displayed as either positive or negative. Alternatively, the luminescence counts can be provided, if preferred.
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of the National Institute of Infectious Diseases (NIID),
Tokyo, Japan: A/duck/Alberta/35/76 (H1N1), A/duck/
Germany/1215/73 (H2N3), A/duck/Ukraine/1/63 (H3N8),
A/duck/Czechoslovakia/56 (H4N6), A/turkey/Massachusetts/
3740/65 (H6N2), A/duck/Hong Kong/301/78 (H7N1), A/
turkey/Ontario/6118/68 (H8N4), A/turkey/Wisconsin/1/
66 (H9N2), A/chicken/Germany/N/49 (H10N7), A/duck/
England/56 (H11N6), A/duck/Alberta/60/76 (H12N5), A/
gull/Maryland/704/77 (H13N6), A/mallard/Gurjev/263/82
(H14N5), and A/duck/Australia/341/83 (H15N8). All
viruses were propagated in the allantoic cavity of 10-day-
old embryonated chicken eggs. The virus titer and RNA
copy number of the matrix gene were determined by the
50% tissue culture infective dose (TCID50) using Madin–
Darby Canine Kidney (MDCK) cells and by quantitative
real-time RT-PCR as described previously [18], respectively.
Clinical samples
Throat swabs or tracheal aspirates were collected at the
point of admission from patients with clinical H5N1
virus infections in Northern Vietnam from 2007 to 2010.
Clinical specimens were diluted in about 2 ml of viral
transport medium (VTM) consisting of MEM medium
supplemented with 1% of 2.92% L-glutamine, 1% of
Penicillin- Streptomycin (10,000U/ml and 10,000 μg/ml,
respectively), 1.5% of 37.5% NaHCO3 and 0.05% of
250 μg/ml Fungizon (all from Life Technologies, Carlsbad,
CA), packed into a cooling box and sent to the National
Influenza Center, National Institute of Hygiene and
Epidemiology (NIHE) for H5N1 HPAI virus detection by
conventional RT-PCR. Clinical specimens (nasal and
throat swabs) from Southern Vietnam collected in 2009
and 2012 were diluted in about 2 ml of VTM and sent to
the National Influenza Center, Pasteur Institute in Ho Chi
Minh City (PI-HCMC) for H5N1 HPAI virus detection by
real-time RT-PCR. After a part of clinical specimen was
used for RNA extraction, the remaining volume was ali-
quoted into cryotubes and maintained at −80°C until
further analysis. The collection of clinical samples was
approved by the institutional review boards of NIHE and
PI-HCMC. All nasopharyngeal aspirates from patients,
including seasonal and non-influenza, were collected after
obtaining patient’s written informed consent.
Results and discussion
Different combinations of anti-H5 HA mAbs [17] and a
pair of biotinylated OM-b and ALP-conjugated 1C10
mAbs were selected for H5 HA detection.
The H5/A kit contains two sets of mAb mixtures to
detect H5 HA simultaneously with NP antigens which
are common to all influenza A viruses. This combination
is important for the definitive diagnosis of H5 HPAI
virus infection. When a clinical specimen is loaded into
a reservoir tank in the cartridge, which is placed in the
machine along with two reaction vessels, an automatic
diagnosis for H5N1 HPAI virus infection is provided
(Figure 1). To determine the sensitivity of the H5/A kit,
inactivated H5N1 HPAI virus of representative clades
(Table 1) were used. The quantities of viruses were
determined by TCID50 and quantitative real-time RT-
PCR targeting the universally conserved matrix gene of
influenza A. These viruses were serially 10-fold diluted
and the luminescence counts were measured. Then, the
virus TCID50 titers at each dilution were calculated and
plotted as shown in Figure 2. The dotted line indicates
the lowest detection threshold, which was determined by
adding four standard deviations to the average of eight
measurements of the negative control. Thus, the
POCube detected these viruses at a titer equivalent to
101–103 TCID50.
We also confirmed that the kit detected type A anti-
gens, but not H5 antigens, in all other subsets of type A
influenza viruses examined (H1N1, H2N3, H3N8, H4N6,
H6N2, H7N1 H8N4, H9N2, H10N7, H11N6, H12N5,
H13N6, H14N5, and H15N8) including strains recently
endemic in Japan (mostly H1N1pdm or type B), indicat-
ing that the kit is highly specific to H5 HA (data not
shown). Furthermore, we tested clinical swab specimens
taken from 15 seasonal influenza and 30 non-influenza
patients and found no false positives of H5. Thus, the
POCube system offers a simple, safe, and rapid diagnostic
system, and is expected to be highly sensitive compared
with existing commercial kits that use immunochromato-
graphy (IC) technology.
We tested clinical specimens (throat swabs) from nine
patients infected with the H5N1 HPAI virus (identifica-
tion confirmed by molecular diagnosis using RT-PCR) in
NIHE during 2007 to 2010 (clade 2.3.4) and compared
the detection rate of our H5/A kit by POCube with that
of the commercially available rapid influenza diagnostic
test (RIDT), (Table 2). The clade was confirmed by
genetic analysis of MDCK cells and/or embryonated egg
isolation (data not shown). Luminescence counts of
POCube were categorized as positive or negative as
described in the Methods. In 2007, clinical specimens
were collected at two time points from patient A,
whereas they were only collected once from each of the
other patients (B–I). All the specimens were already
Table 1 H5N1 viruses used for titration






1 A/Vietnam/1194/2004 (NIBRG-14) 1.1 7.0 2.88
2 A/Indonesia/5/2005 (PR8-IBCDC) 2.1.3.2 7.4 3.81
3 A/turkey/Turkey/1/2005 (NIBRG-23) 2.2.1 5.9 1.60
4 A/Anhui/1/2005 (PR8-IBCDC RG-5) 2.3.4 8.3 3.73
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diluted approximately 40-fold with VTM. We re-examined
these clinical specimens for H5 HA RNA using conven-
tional RT-PCR to assess the quality of the frozen samples:
all were positive. One of these 10 samples (sample No. 9 of
patient H) was H5-negative but type A-positive (Table 2),
indicating that the abundance of viral particles was very
low. One sample (No. 2 of patient A) was H5-positive but
type A-negative. The quantity of viral particles was lower
in this sample (No. 2) than in the sample (No. 1) that was
collected at an earlier time point from the same patient
(luminescence count of type A was 3,582 in sample No. 2
vs. 122,693 in sample No. 1). By contrast, a widely used
commercially available RIDT based on IC using an anti-
NP Ab showed very poor sensitivity, with only 10% of
samples indicating a positive result. Furthermore, because
the influenza NP is highly conserved, this kit cannot
discriminate the A/H5N1 subtype from other influenza
virus subtypes.
The H5/A kit was also evaluated using nine clinical
specimens collected from one patient (J) in 2009 and
from three patients (K–M) in 2012 (Table 3). These
specimens were stored at the PI-HCMC after H5N1
HPAI virus (clade 1.1) infection was confirmed by gen-
etic analysis of MDCK cells (data not shown). In patient
J, throat swabs taken at two time points, a nasal swab,
and a serum sample were all H5-positive and had similar
luminescence counts of 5,282, 5,358, 5,344, and 6,448,
respectively. In patient L, a throat swab was H5- and
type A-negative, whereas a nasal swab was positive for
both. In patient M, a throat swab was H5-positive and
type A-negative, whereas a nasal swab was H5- and type
A-positive. These results suggest that secretion of the
Table 2 Detection of H5N1 HPIA virus in clinical specimens
in NIHE, Hanoi (clade 2.3.4)
Year Patient ID Test no. POCube H5/A1 RIDT2
H5 HA A NP
2007
A 1 + + +
2 + - -
B 3 + + -
C 4 + + -
D 5 + + +/−3
2009
E 6 + + -
F 7 + + -
G 8 + + -
2010
H 9 - + -
I 10 + + -
% positive 90 90 10
1The POCube machine shows the results for H5 and type A viruses as “+” or
“–” based on a predetermined cut-off index set (calculated as described in the
“Methods”).
2RIDT: commercial kit detecting universal NP antigen of influenza A virus
(ESPLINE® Influenza A&B-N).
3Uncertain.
Table 3 Detection of H5N1 HPIA virus in clinical specimens
in PI-HCMC (clade 1.1)
Year Patient ID Test no. Specimen POCube H5/A RIDT
H5 HA A NP
2009
J 11 Throat + + -
12 Throat + + -
13 Nasal + + -
14 Serum + + -
2012
K 15 Throat + + +
L 16 Throat - - -
17 Nasal + + -
M 18 Throat + - -
19 Nasal + + -
% positive 88.9 77.8 11.1
Table 4 Summary of H5N1 HPIA virus detection in clinical
specimens from Vietnam
H5N1




by RIDTPositive Negative Suspicious
+/+ −/− +/− −/+
Clade 2.3.4 8 0 1 1 80.0 10
Clade 1.1 7 1 1 0 77.8 11.1
Total 15 1 2 1 78.9 10.5
Figure 2 The sensitivity of the H5/A kit. H5N1 HPAI virus strains
(Table 1) were serially diluted 10-fold, H5 HA antigens were measured
using the POCube system, and the luminescence counts for each
TCID50 virus titer calculated according to each dilution were plotted.
The dotted line indicates the lowest detection threshold, which was
determined by adding four standard deviations to the average of eight
measurements of the negative control.
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virus is more abundant in the nasal mucosa than in the
throat, and are not consistent with previous reports
[19,20]. Also, the timing for sampling may affect the
detection efficiency. However, because the number of
samples tested in this study was very small, further test-
ing is needed. The findings indicate that when H5N1
HPAI virus infection is suspected, it is important to
collect samples from more than one anatomical location
(i.e., throat and nose) and/or at more than one time point.
When samples are H5-positive but type A-negative,
such as was the case for patient M (luminescence counts
of H5 and type A were 4,071 and 2,622, respectively),
the test needs to be repeated or confirmed by genetic
analysis. This may occur when the level of virus antigen
is at the threshold of detection, such as was the case for
sample No. 2 of patient A. Again, the commercially
available RIDT showed poor sensitivity, with only one of
nine samples testing positive for type A.
Table 4 shows a summary of the results of the POCube
H5/A kit test in samples collected from Vietnam, which
detected 77.8% and 80.0% of clade 1.1 and clade 2.3.4
H5N1 HPAI virus infections, respectively. In these sam-
ples, the POCube test detected 78.9% of H5N1 HPAI virus
infections, whereas the RIDT detected only 10.5%. This
was probably because POCube is a highly sensitive chemi-
luminescence detection system that uses mAbs with a
high affinity to H5 HA and also analyzes a much larger
sample volume than the RIDT (up to 180 μl for POCube
vs. about 5 μl for RIDT). Considering that only one in 19
samples tested negative for both H5 and A antigens, the
POCube H5/A kit is highly useful to detect H5N1 HPAI
virus infections in clinical settings. In this study, samples
were diluted in VTM (about 2 ml); however, we believe
the detection rate will improved even further if clinical
swabs are tested with a reduced volume of this medium.
H5 HA HPAI virus detection using POCube and the
H5/A kit is a highly sensitive and simple rapid diagnostic
system that can be completed within 15 minutes. During
the preparation of this manuscript, Sakurai et al.
reported a 10–100-fold more sensitive detection of H5
HA using fluorescent beads and an improved IC method
[21]; however, the clinical effectiveness of this method
remains to be evaluated. We recently determined the
epitopes of our anti-H5HA mAbs and found that OM-b,
one of mAbs used for the H5/A kit, was broadly reactive
to various clades of H5N1 influenza virus isolates in
Asia, indicating that ther kit is quite useful for the
diagnosis of H5N1 infection in Asian counties [22].
Conclusions
The POCube system using the H5/A kit is useful for the
rapid detection of H5N1 HPAI virus infections in
humans in hospitals and other clinical settings where
technical resources are limited.
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